We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
JBL Boosts Healthcare Portfolio With Strategic Buyout: Stock to Gain?
Read MoreHide Full Article
Jabil, Inc. (JBL - Free Report) recently announced that it has completed the acquisition of Pharmaceutics International, Inc. for an undisclosed amount. Based in Hunt Valley, MD, Pharmaceutics is a prominent contract development and manufacturing organization (CDMO) that offers tailored solutions for each phase of the drug development journey.
Pharma companies encounter several challenges during lengthy and complex processes of drug development, manufacturing and distribution. Enterprises in the CDMO space offer a multitude of services, such as formulation, analytical services in the initial drug development stage, manufacturing of drug substances, packaging and clinical trials that streamline the pharma development journey. The acquisition of Pharmaceutics International marks Jabil’s entry into the CDMO market.
Will JBL Stock Benefit From This Buyout?
Pharmaceutics International boasts leading-edge manufacturing facilities that include the formulation development center, analytical and microbiology laboratories, an aseptic facility for injectables like vials and syringes, dedicated manufacturing suites for oral products, containment suites for handling high-potency compounds and hormones.
Jabil boasts an extensive portfolio of pharmaceutical offerings, which include auto-injectors, cold chain management, dry powder inhalers, insulin pens, metered dose inhalers, needle-free injection systems and more. Integration of Pharmaceutics International’s extensive capabilities will significantly bolster Jabil’s pharmaceutical product offerings and will enable it to develop more advanced solutions for pharma companies. Following the acquisition, Pharmaceutics International will also gain from Jabil’s global reach, cutting edge automation, supply chain efficiency and strong worldwide network, which will enable it to scale up production per the evolving market dynamics.
The CDMO market is expected to grow at a substantial rate in the upcoming years. With the acquisition of Pharmaceutics International, Jabil is well-positioned to capitalize on this emerging market trend.
JBL’s Stock Price Movement
Shares of Jabil have gained 24.7% over the past year compared with the industry’s growth of 65.4%.
Image Source: Zacks Investment Research
JBL’s Zacks Rank and Key Picks
Jabil currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader industry have been discussed below.
In the last reported quarter, it delivered an earnings surprise of 5.10%. Keysight is expected to benefit from the growing proliferation of electronic content in vehicles, momentum in space and satellite applications, and rising adoption of driver-assistance systems globally.
InterDigital (IDCC - Free Report) carries a Zacks Rank #2 at present. In the last reported quarter, it delivered an earnings surprise of 114.47%.
It is a pioneer in advanced mobile technologies that enable wireless communications and capabilities. The company designs and develops a wide range of advanced technology solutions used in digital cellular, wireless 3G, 4G and IEEE 802-related products and networks.
Zillow Group, Inc. (ZG - Free Report) carries a Zacks Rank #2 at present. In the last reported quarter, it delivered an earnings surprise of 9.38%. ZG delivered an earnings surprise of 25.47%, on average, in the trailing four quarters. The company is witnessing solid momentum in rental revenues, driven by growth in multi and single-family listings, which is a positive factor.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
JBL Boosts Healthcare Portfolio With Strategic Buyout: Stock to Gain?
Jabil, Inc. (JBL - Free Report) recently announced that it has completed the acquisition of Pharmaceutics International, Inc. for an undisclosed amount. Based in Hunt Valley, MD, Pharmaceutics is a prominent contract development and manufacturing organization (CDMO) that offers tailored solutions for each phase of the drug development journey.
Pharma companies encounter several challenges during lengthy and complex processes of drug development, manufacturing and distribution. Enterprises in the CDMO space offer a multitude of services, such as formulation, analytical services in the initial drug development stage, manufacturing of drug substances, packaging and clinical trials that streamline the pharma development journey. The acquisition of Pharmaceutics International marks Jabil’s entry into the CDMO market.
Will JBL Stock Benefit From This Buyout?
Pharmaceutics International boasts leading-edge manufacturing facilities that include the formulation development center, analytical and microbiology laboratories, an aseptic facility for injectables like vials and syringes, dedicated manufacturing suites for oral products, containment suites for handling high-potency compounds and hormones.
Jabil boasts an extensive portfolio of pharmaceutical offerings, which include auto-injectors, cold chain management, dry powder inhalers, insulin pens, metered dose inhalers, needle-free injection systems and more. Integration of Pharmaceutics International’s extensive capabilities will significantly bolster Jabil’s pharmaceutical product offerings and will enable it to develop more advanced solutions for pharma companies. Following the acquisition, Pharmaceutics International will also gain from Jabil’s global reach, cutting edge automation, supply chain efficiency and strong worldwide network, which will enable it to scale up production per the evolving market dynamics.
The CDMO market is expected to grow at a substantial rate in the upcoming years. With the acquisition of Pharmaceutics International, Jabil is well-positioned to capitalize on this emerging market trend.
JBL’s Stock Price Movement
Shares of Jabil have gained 24.7% over the past year compared with the industry’s growth of 65.4%.
Image Source: Zacks Investment Research
JBL’s Zacks Rank and Key Picks
Jabil currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader industry have been discussed below.
Keysight Technologies, Inc. (KEYS - Free Report) has a Zacks Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the last reported quarter, it delivered an earnings surprise of 5.10%. Keysight is expected to benefit from the growing proliferation of electronic content in vehicles, momentum in space and satellite applications, and rising adoption of driver-assistance systems globally.
InterDigital (IDCC - Free Report) carries a Zacks Rank #2 at present. In the last reported quarter, it delivered an earnings surprise of 114.47%.
It is a pioneer in advanced mobile technologies that enable wireless communications and capabilities. The company designs and develops a wide range of advanced technology solutions used in digital cellular, wireless 3G, 4G and IEEE 802-related products and networks.
Zillow Group, Inc. (ZG - Free Report) carries a Zacks Rank #2 at present. In the last reported quarter, it delivered an earnings surprise of 9.38%. ZG delivered an earnings surprise of 25.47%, on average, in the trailing four quarters. The company is witnessing solid momentum in rental revenues, driven by growth in multi and single-family listings, which is a positive factor.